We provide you with 20 years of free, institutional-grade data for DTIL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DTIL. Explore the full financial landscape of DTIL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Precision BioSciences, Inc(NASDAQ:DTIL) 
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunoth...
Website: http://precisionbiosciences.com/
Founded: 2006
CEO: Matthew Kane
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Share this website to your friends
The information provided in this report about DTIL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.